Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis - PubMed
3 hours ago
- #neurosurgery
- #progestogen
- #meningioma
- Progestogen use, particularly high-dose macroprogestogens, may increase the risk of intracranial meningioma.
- Cyproterone acetate (CPA) showed a significant association with increased meningioma risk (pooled-OR 12.36).
- Depot medroxyprogesterone acetate also increased the risk (pooled-OR 2.68), though with lower certainty.
- Other progestogens like chlormadinone acetate (CMA), nomegestrol acetate (NOMAC), promegestone, medrogestone, and desogestrel showed signals of increased risk.
- No increased risk was found for norgestrel, levonorgestrel, progesterone, dydrogesterone, or spironolactone.
- Meningiomas linked to progestogens were predominantly located in the anterior/middle skull base, with higher malignancy rates for CPA, CMA, and NOMAC.
- Regression after withdrawal was observed for CPA and NOMAC.
- The study highlights the need for transparent patient information and careful clinical/imaging follow-up.